تحميل...
Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials
BACKGROUND: Several clinical trials have shown an increased risk of hypertension with bevacizumab when added to chemotherapy in different types of malignancy; however, the risks of other significant adverse events besides hypertension, specifically in breast cancer, have not been completely elucidat...
محفوظ في:
| الحاوية / القاعدة: | Ther Clin Risk Manag |
|---|---|
| المؤلفون الرئيسيون: | , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Dove Medical Press
2018
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5939922/ https://ncbi.nlm.nih.gov/pubmed/29765225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S148840 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|